Wave Life Sciences（股票代码：WVE）今日盘前股价大涨5.18%，引起市场广泛关注。
消息面上，该公司公布了用于治疗肥胖症的WVE-007一期临床试验的中期数据，显示在最低治疗剂量下，体重减轻效果与GLP-1类似，且未出现肌肉损失。具体数据显示，单次240毫克剂量的WVE-007可使内脏脂肪减少9.4%，全身脂肪减少4.5%，瘦体重增加3.2%。此外，WVE-007的安全性和耐受性良好，仅出现轻微的不良事件。
这一积极数据增强了市场对Wave Life Sciences在肥胖症治疗领域潜力的信心。值得注意的是，WVE-007采用了一种全新的RNA疗法机制，与传统的GLP-1受体激动剂有本质区别，其“减脂不减肌”的效果直接解决了当前减肥药的最大痛点。此外，基于RNA疗法的特性，WVE-007可能实现每年仅1-2次的给药频率，这将极大提高患者依从性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.